Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats
by
Kitaichi Y, Inoue T, Izumi T, Nakagawa S, Tanaka T, Masui T, Koyama T.
Department of Psychiatry, Neural Function,
Hokkaido University Graduate School of Medicine,
North 15, West 7, Kita-ku, Sapporo 060-8638, Japan.
ykita@med.hokudai.ac.jp
Eur J Pharmacol. 2008 Apr 28;584(2-3):285-90.
ABSTRACTRecent studies have shown that dopamine agonists are useful for the treatment of not only Parkinson's disease, but also major depressive disorders. However, while these dopamine agonists provide a new treatment strategy for major depressive disorders, such as treatment-resistant cases, the antidepressant effect of dopamine agonists has yet to be investigated. To examine the mechanism of the antidepressive effect of dopamine agonists, we investigated the acute effect of the dopamine receptor agonist, cabergoline, and the serotonin-noradrenaline reuptake inhibitor, milnacipran, on extracellular noradrenaline, dopamine and serotonin concentrations in the rat medial prefrontal cortex. There was a greater increase in extracellular noradrenaline concentrations when acute milnacipran (30 mg/kg intraperitoneally) was administered after acute high-dose cabergoline (1 and 2 mg/kg subcutaneously) than when acute milnacipran was administered following acute vehicle or low-dose cabergoline (0.25 mg/kg subcutaneously). There were no significant differences noted in the dopamine or serotonin concentrations. These results suggest that the addition of cabergoline has the potential to strengthen the antidepressant effects of milnacipran and that the mechanism of action of the antidepressive effect of dopamine agonists might be due to enhancement of induced increases of extracellular noradrenaline.Cabergoline
Dopaminergics
Cabergoline.com
Caffeine and Parkinson's disease
Cabergoline as a neuroprotectant
Dopamine agonists for Parkinson's disease
Parkinsonian signs/symptoms in depressives
Cabergoline (Dostinex ) for Parkinson's disease
Cabergoline (Dostinex) v bromocriptine (Parlodel)
Refs
and further readingHOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family
